A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma

Despite the introduction of multiple new drugs and combination therapies, conventional dexamethasone remains a cornerstone in the treatment of multiple myeloma (MM). Its application is, however, limited by frequent adverse effects of which the increased infection rate may have the strongest clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Metselaar, Josbert, Lammers, Twan, Boquoi, Amelie, Fenk, Roland, Testaquadra, Fabio, Schemionek, Mirle, Kiessling, Fabian, Isfort, Susanne, Wilop, Stefan, Crysandt, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981510/
https://www.ncbi.nlm.nih.gov/pubmed/36592287
http://dx.doi.org/10.1007/s13346-022-01268-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981510/
https://www.ncbi.nlm.nih.gov/pubmed/36592287
http://dx.doi.org/10.1007/s13346-022-01268-6

Ejemplares similares